We provide a clinically useful, reliable, comprehensive, up-to-date, evidence-based drug-drug interaction resource, freely available to healthcare workers, patients and researchers.
The Liverpool Drug Interaction Group was established in 1999 by members of the Department of Pharmacology at the University of Liverpool to provide a freely available drug-drug interaction resource for drugs used to treat HIV infection. Since then, our activity has expanded to include drug interaction information for the treatment of hepatitis B infection, hepatitis C infection, hepatitis D infection, primary biliary cholangitis and various cancers (in collaboration with Radboud UMC, Netherlands). These interaction resources can be found at:
The COVID-19 pandemic has affected every country in the world. It is well documented that those most susceptible to the worst outcomes of COVID-19 are the immunocompromised and those with underlying comorbidities. Therefore, patients requiring treatment for COVID-19 will also be on additional medication, posing a risk for drug-drug interactions (DDIs). In order to address this, the Liverpool Drug Interactions website team developed this freely available drug interactions resource to provide information on the likelihood of interactions between the experimental agents used for the treatment of COVID-19 and commonly prescribed co-medications.
The Liverpool Drug Interactions resources are widely utilised, supporting international guidelines and policies. We strongly believe that drug information should be offered free of charge, be independent, and be evidence-based and transparent. We are convinced that quality of care is vitally important, particularly when faced with all the challenges of a new disease and where patient harms from DDIs may pass unnoticed. We actively promote the use of our resources to healthcare providers and patients to enable rapid screening of DDIs.
We are rightly expected to conduct ourselves in an ethical and transparent manner – without bias, and without the perception of bias. Equally, support from the Pharmaceutical Industry, Societies and Charities has yielded patient benefits which would not otherwise have accrued through exclusive reliance on local health services or funding agencies.
Information presented relates only to known or suspected effects of interacting medications, and is based on relevant data in the public domain. No clinical advice is given or implied, clinicians must exercise their own judgement in relation to the risks and benefits of combining drugs, which depend on factors beyond pharmacokinetic interactions between two drugs. The University of Liverpool shall not be held responsible for the application or use of any information it gives and the user shall hold the University of Liverpool harmless against any consequences arising from the same.